Statin therapy decreased the recurrence frequency of atrial fibrillation after electrical cardioversion: a

Peng Yan1, Pingshuan Dong1, Zhijuan Li1

  • 1Department of Cardiology, First Affiliated Hospital, Henan Science and Technology University, Luoyang, Henan, China (mainland).

Insights

Statins significantly reduce atrial fibrillation (AF) recurrence after electrical cardioversion (EC). This meta-analysis confirms statin therapy, particularly atorvastatin and rosuvastatin, benefits patients by preventing AF relapse.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) recurrence post-electrical cardioversion (EC) remains a clinical challenge.
  • The role of statin agents in preventing AF relapse after EC is not well-defined.

Purpose of the Study:

  • To evaluate the efficacy of statin agents in preventing AF recurrence following EC.
  • To conduct a meta-analysis of randomized controlled trials (RCTs) assessing this clinical outcome.

Main Methods:

  • Systematic literature search of major databases (Medline, EMBASE, Web of Science, Cochrane).
  • Inclusion of RCTs comparing statin therapy versus placebo or conventional treatment in post-EC AF patients.
  • Meta-analysis of pooled results presented as risk ratios (RRs) with 95% confidence intervals (CIs).

Main Results:

  • Analysis of 5 RCTs involving 524 patients.
  • Statins significantly decreased AF recurrence post-EC (RR=0.76, p=0.004).
  • Beneficial effects observed with atorvastatin and rosuvastatin, particularly in younger patients (<65 years) and within 12 months post-EC.

Conclusions:

  • Statin administration, specifically atorvastatin or rosuvastatin, is effective in reducing AF recurrence post-EC.
  • Statins represent a beneficial therapeutic option for maintaining sinus rhythm after electrical cardioversion.
Abstract

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.4K
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
642
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
650